10 results on '"Hong, Seungpyo"'
Search Results
2. Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients.
- Author
-
Poellmann, Michael, Bu, Jiyoon, Liu, Stanley, Wang, Andrew, Seyedin, Steven, Chandrasekharan, Chandrikha, Hong, Heejoo, Kim, YoungSoo, Caster, Joseph, and Hong, Seungpyo
- Subjects
Circulating tumor cell ,Convolutional neural network ,Gastrointestinal cancer ,Liquid biopsy ,Humans ,Neoplastic Cells ,Circulating ,Leukocytes ,Mononuclear ,Biosensing Techniques ,Biomarkers ,Nanotechnology ,Gastrointestinal Neoplasms ,Biomarkers ,Tumor - Abstract
A highly sensitive, circulating tumor cell (CTC)-based liquid biopsy was used to monitor gastrointestinal cancer patients during treatment to determine if CTC abundance was predictive of disease recurrence. The approach used a combination of biomimetic cell rolling on recombinant E-selectin and dendrimer-mediated multivalent immunocapture at the nanoscale to purify CTCs from peripheral blood mononuclear cells. Due to the exceptionally high numbers of CTCs captured, a machine learning algorithm approach was developed to efficiently and reliably quantify abundance of immunocytochemically-labeled cells. A convolutional neural network and logistic regression model achieved 82.9% true-positive identification of CTCs with a false positive rate below 0.1% on a validation set. The approach was then used to quantify CTC abundance in peripheral blood samples from 27 subjects before, during, and following treatments. Samples drawn from the patients either prior to receiving radiotherapy or early in chemotherapy had a median 50 CTC ml-1 whole blood (range 0.6-541.6). We found that the CTC counts drawn 3 months post treatment were predictive of disease progression (p = .045). This approach to quantifying CTC abundance may be a clinically impactful in the timely determination of gastrointestinal cancer progression or response to treatment.
- Published
- 2023
3. Peptide–nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms?
- Author
-
Jeong, Woo-jin, Bu, Jiyoon, Kubiatowicz, Luke J., Chen, Stephanie S., Kim, YoungSoo, and Hong, Seungpyo
- Published
- 2018
- Full Text
- View/download PDF
4. Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC).
- Author
-
Lee, Taehee, Rawding, Piper A., Bu, Jiyoon, Hyun, Sunghee, Rou, Woosun, Jeon, Hongjae, Kim, Seokhyun, Lee, Byungseok, Kubiatowicz, Luke J., Kim, Dawon, Hong, Seungpyo, and Eun, Hyuksoo
- Subjects
ALPHA fetoproteins ,ALBUMINS ,ALKALINE phosphatase ,MACHINE learning ,METASTASIS ,GENE expression ,EXTRACELLULAR space ,TUMOR markers ,HEPATOCELLULAR carcinoma ,NUCLEIC acids ,ALGORITHMS ,ASPARTATE aminotransferase ,ALANINE aminotransferase ,BILIRUBIN - Abstract
Simple Summary: Circulating cell-free DNA (cfDNA) has attracted a great deal of scientific interest as a predictive biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC). HCC result in high mortality due to the absence of blood biomarkers for early diagnosis and prognosis. We established cfD
HCC as a new scoring system by applying a machine learning algorithm that integrates the expression profiles of cfDNA. Based on this, it was possible to accurately predict the clinico-pathological characteristics of patients with HCC as well as improve their survival. (1) Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Although various serum enzymes have been utilized for the diagnosis and prognosis of HCC, the currently available biomarkers lack the sensitivity needed to detect HCC at early stages and accurately predict treatment responses. (2) Methods: We utilized our highly sensitive cell-free DNA (cfDNA) detection system, in combination with a machine learning algorithm, to provide a platform for improved diagnosis and prognosis of HCC. (3) Results: cfDNA, specifically alpha-fetoprotein (AFP) expression in captured cfDNA, demonstrated the highest accuracy for diagnosing malignancies among the serum/plasma biomarkers used in this study, including AFP, aspartate aminotransferase, alanine aminotransferase, albumin, alkaline phosphatase, and bilirubin. The diagnostic/prognostic capability of cfDNA was further improved by establishing a cfDNA score (cfDHCC ), which integrated the total plasma cfDNA levels and cfAFP-DNA expression into a single score using machine learning algorithms. (4) Conclusion: The cfDHCC score demonstrated significantly improved accuracy in determining the pathological features of HCC and predicting patients' survival outcomes compared to the other biomarkers. The results presented herein reveal that our cfDNA capture/analysis platform is a promising approach to effectively utilize cfDNA as a biomarker for the diagnosis and prognosis of HCC. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. Branched, dendritic, and hyperbranched polymers in liquid biopsy device design.
- Author
-
Poellmann, Michael J., Rawding, Piper, Kim, DaWon, Bu, Jiyoon, Kim, YoungSoo, and Hong, Seungpyo
- Abstract
The development of minimally invasive tests for cancer diagnosis and prognosis will aid in the research of new treatments and improve survival rates. Liquid biopsies seek to derive actionable information from tumor material found in routine blood samples. The relative scarcity of tumor material in this complex mixture makes isolating and detecting cancerous material such as proteins, circulating tumor DNA, exosomes, and whole circulating tumor cells a challenge for device engineers. This review describes the chemistry and applications of branched and hyperbranched to improve the performance of liquid biopsy devices. These polymers can improve the performance of a liquid biopsy through several mechanisms. For example, polymers designed to increase the affinity of capture enhance device sensitivity. On the other hand, polymers designed to increase binding avidity or repel nonspecific adsorption enhance device specificity. Branched and hyperbranched polymers can also be used to amplify the signal from small amounts of detected material. The further development of hyperbranched polymers in liquid biopsy applications will enhance device capabilities and help these critical technologies reach the oncology clinic where they are sorely needed. This article is categorized under:Diagnostic Tools > BiosensingDiagnostic Tools > Diagnostic Nanodevices [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Clinical indications for, and the future of, circulating tumor cells.
- Author
-
Moon, Dominic H., Lindsay, Daniel P., Hong, Seungpyo, and Wang, Andrew Z.
- Subjects
- *
CLINICAL indications , *CANCER cells , *CANCER diagnosis , *TUMOR treatment , *METASTASIS - Abstract
Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making. These include using CTCs as a screening tool for diagnosis, liquid biopsy for molecular profiling, predictive biomarker to specific therapies, and monitoring tool to assess response and guide changes to treatment. CTCs have unique advantages vs circulating tumor DNA in this endeavor. Indications for CTCs in daily practice will expand as isolation techniques improve and clinical studies validating their utility continue to grow. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Integration of biomimicry and nanotechnology for significantly improved detection of circulating tumor cells (CTCs).
- Author
-
Myung, Ja Hye, Park, Sin-jung, Wang, Andrew Z., and Hong, Seungpyo
- Subjects
- *
TUMOR treatment , *TUMOR diagnosis , *BIOMIMICRY , *CANCER cells , *ETIOLOGY of cancer , *CLINICAL trials - Abstract
Circulating tumor cells (CTCs) have received a great deal of scientific and clinical attention as a biomarker for diagnosis and prognosis of many types of cancer. Given their potential significance in clinics, a variety of detection methods, utilizing the recent advances in nanotechnology and microfluidics, have been introduced in an effort of achieving clinically significant detection of CTCs. However, effective detection and isolation of CTCs still remain a tremendous challenge due to their extreme rarity and phenotypic heterogeneity. Among many approaches that are currently under development, this review paper focuses on a unique, promising approach that takes advantages of naturally occurring processes achievable through application of nanotechnology to realize significant improvement in sensitivity and specificity of CTC capture. We provide an overview of successful outcome of this biomimetic CTC capture system in detection of tumor cells from in vitro, in vivo, and clinical pilot studies. We also emphasize the clinical impact of CTCs as biomarkers in cancer diagnosis and predictive prognosis, which provides a cost-effective, minimally invasive method that potentially replaces or supplements existing methods such as imaging technologies and solid tissue biopsy. In addition, their potential prognostic values as treatment guidelines and that ultimately help to realize personalized therapy are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment.
- Author
-
Poellmann, Michael J., Bu, Jiyoon, Kim, DaWon, Iida, Mari, Hong, Heejoo, Wang, Andrew Z., Wheeler, Deric L., Kimple, Randall J., and Hong, Seungpyo
- Subjects
- *
SQUAMOUS cell carcinoma , *HEAD & neck cancer , *CETUXIMAB , *HUMAN papillomavirus , *CHEMORADIOTHERAPY , *NECK - Abstract
Head and neck squamous cell carcinoma (HNSCC) is a common and deadly cancer. Circulating tumor cell (CTC) abundance may a valuable, prognostic biomarker in low- and intermediate-risk patients. However, few technologies have demonstrated success in detecting CTCs in these populations. We prospectively collected longitudinal CTC counts from two cohorts of patients receiving treatments at our institution using a highly sensitive device that purifies CTCs using biomimetic cell rolling and dendrimer-conjugated antibodies. In patients with intermediate risk human papillomavirus (HPV)-positive HNSCC, elevated CTC counts were detected in 13 of 14 subjects at screening with a median of 17 CTC/ml (range 0.2–2986.5). A second cohort of non-metastatic, HPV- HNSCC subjects received cetuximab monotherapy followed by surgical resection. In this cohort, all subjects had elevated baseline CTC counts median of 73 CTC/ml (range 5.4–332.9) with statistically significant declines during treatment. Interestingly, two patients with recurrent disease had elevated CTC counts during and following treatment, which also correlated with growth of size and ki67 expression in the primary tumor. The results suggest that our device may be a valuable tool for evaluating the success of less intensive treatment regimens. • Nanostructured, biomimetic liquid biopsy captured high numbers of HNSCC CTCs. • Trends in CTC abundance predict outcomes in 13/14 HPV- HNSCC patients. • CTC trends show promise in the prognosis of low- and intermediate-risk HNSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients.
- Author
-
Poellmann, Michael J., Bu, Jiyoon, Liu, Stanley, Wang, Andrew Z., Seyedin, Steven N., Chandrasekharan, Chandrikha, Hong, Heejoo, Kim, YoungSoo, Caster, Joseph M., and Hong, Seungpyo
- Subjects
- *
GASTROINTESTINAL cancer , *MACHINE learning , *MONONUCLEAR leukocytes , *CONVOLUTIONAL neural networks , *NANOTECHNOLOGY , *CANCER patients - Abstract
A highly sensitive, circulating tumor cell (CTC)-based liquid biopsy was used to monitor gastrointestinal cancer patients during treatment to determine if CTC abundance was predictive of disease recurrence. The approach used a combination of biomimetic cell rolling on recombinant E-selectin and dendrimer-mediated multivalent immunocapture at the nanoscale to purify CTCs from peripheral blood mononuclear cells. Due to the exceptionally high numbers of CTCs captured, a machine learning algorithm approach was developed to efficiently and reliably quantify abundance of immunocytochemically-labeled cells. A convolutional neural network and logistic regression model achieved 82.9% true-positive identification of CTCs with a false positive rate below 0.1% on a validation set. The approach was then used to quantify CTC abundance in peripheral blood samples from 27 subjects before, during, and following treatments. Samples drawn from the patients either prior to receiving radiotherapy or early in chemotherapy had a median 50 CTC ml−1 whole blood (range 0.6–541.6). We found that the CTC counts drawn 3 months post treatment were predictive of disease progression (p =.045). This approach to quantifying CTC abundance may be a clinically impactful in the timely determination of gastrointestinal cancer progression or response to treatment. • Nanostructured, biomimetic liquid biopsy captured high numbers of GI cancer CTCs. • Machine learning algorithm efficiently enumerated immunocytochemically labeled CTCs. • CTC abundance immediately following treatment predicted disease recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.
- Author
-
Bu, Jiyoon, Nair, Ashita, Kubiatowicz, Luke J., Poellmann, Michael J., Jeong, Woo-jin, Reyes-Martinez, Marco, Armstrong, Andrew J., George, Daniel J., Wang, Andrew Z., Zhang, Tian, and Hong, Seungpyo
- Subjects
- *
MET receptor , *RENAL cell carcinoma , *POLYAMIDOAMINE dendrimers , *CIRCULATING tumor DNA , *BIOMIMETIC materials , *EPIDERMAL growth factor receptors , *CELL adhesion molecules , *ATOMIC force microscopy - Abstract
Sensitive detection of circulating tumor cells (CTCs) from patients' peripheral blood facilitates on-demand monitoring of tumor progression. However, clinically significant capture of renal cell carcinoma CTCs (RCC-CTCs) remains elusive due to their heterogenous surface receptor expression. Herein, a novel capture platform is developed to detect RCC-CTCs through integration of dendrimer-mediated multivalent binding, a mixture of antibodies, and biomimetic cell rolling. The nanoscale binding kinetics measured using atomic force microscopy reveal that dendrimer-coated surfaces exhibit an order of magnitude enhancement in off-rate kinetics compared to surface without dendrimers, which translated into cell capture improvements by ~60%. Selectin-induced cell rolling facilitates surface recruitment of cancer cells, further improving cancer cell capture by up to 1.7-fold. Lastly, an antibody cocktail targeting four RCC-CTC surface receptors, which included epithelial cell adhesion molecule (EpCAM), carbonic anhydrase IX (CA9), epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (c-Met), improves the capture of RCC cells by up to 80%. The optimal surface configuration outperforms the conventional assay solely relying on EpCAM, as demonstrated by detecting significantly more CTCs in patients' samples (9.8 ± 5.1 vs. 1.8 ± 2.0 CTCs mL-1). These results demonstrate that the newly engineered capture platform effectively detects RCC-CTCs for their potential use as tumor biomarkers. • Three effective CTC isolation strategies were integrated for RCC-CTC capture. • A new platform has been tested from nanoscale analysis to clinical application. • Dendrimer nanoparticles exploited the strong multivalent binding to the tumor cells. • Recruitment of the flowing CTCs via cell rolling enhanced capture of RCC cells. • The combination of the 4 antibodies allowed sensitive detection of RCC cells. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.